Semmelweis Egyetem I. sz. Belgyógyászati Klinika
About Semmelweis Egyetem I. sz. Belgyógyászati Klinika
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
4
Astex Pharmaceuticals, Inc.
2
Pfizer
2
Applied Molecular Transport
1
Aziende Chimiche Riunite Angelini Francesco S.p.A
1
Baxalta now part of Shire
1
Camurus AB
1
Fresenius Kabi SwissBioSim GmbH
1
Hoffmann-La Roche
1
Prothena Biosciences Ltd.
1
RDD Pharma Ltd
1
Clinical Trials at Semmelweis Egyetem I. sz. Belgyógyászati Klinika
During the past decade, Semmelweis Egyetem I. sz. Belgyógyászati Klinika conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 4 clinical trials were completed, i.e. on
average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
2010-12-06
2016-12-20
Completed
224
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
2012-02-01
2013-01-01
Completed
304
A Long-term Extension Study of PCI-32765 (Ibrutinib)
2013-09-09
2027-01-29
Enrolling by invitation
700
The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients
2014-11-01
2015-07-01
Completed
19
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
2015-07-01
2023-05-01
Active, not recruiting
230
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
2017-03-16
2020-06-01
Completed
302
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
2017-10-05
2024-08-16
Active, not recruiting
416
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Astex Pharmaceuticals, Inc." with 2 trials
sponsored, "Pfizer" with 2 trials sponsored, "Applied Molecular Transport" with 1 trials sponsored and "Aziende Chimiche Riunite Angelini Francesco S.p.A"
with 1 trials sponsored. Other sponsors include 1 different institutions and
companies that sponsored additional 11 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika"
#1 collaborator was "Chiltern International Inc." with 1 trials as a collaborator and "Pharmacyclics LLC." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Semmelweis Egyetem I. sz. Belgyógyászati Klinika
According to Clinical.Site data, the most researched conditions in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" are
"Acute Myeloid Leukemia" (1 trials), "Amyloidosis" (1 trials), "Chronic Graft Versus Host Disease" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials) and "Crohn's Disease" (1 trials). Many other conditions were trialed in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" in a lesser frequency.
Clinical Trials Intervention Types at Semmelweis Egyetem I. sz. Belgyógyászati Klinika
Most popular intervention types in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" are "Drug" (15 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (6 trials), "AMT-101 (oral)-Dose A" (1 trials), "AMT-101 (oral)-Dose B" (1 trials), "ASTX660" (1 trials) and "Axitinib (AG-013736)" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Semmelweis Egyetem I. sz. Belgyógyászati Klinika
The vast majority of trials in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika" are
14 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at Semmelweis Egyetem I. sz. Belgyógyászati Klinika
Currently, there are NaN active trials in "Semmelweis Egyetem I. sz. Belgyógyászati Klinika".
undefined are not yet recruiting,
3 are recruiting,
4 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 7 completed trials in Semmelweis Egyetem I. sz. Belgyógyászati Klinika,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Semmelweis Egyetem I. sz. Belgyógyászati Klinika, 4 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".